OBJECTIVE Intra-arterial thrombolytic therapy for carotid and vertebrobasilar stroke may result in a more rapid clot lysis and higher recanalization rates than can be achieved with intravenous thrombolysis and thus may warrant the more invasive and time-consuming therapeutic approach. We present an overview of all hitherto completed trials of intra-arterial thrombolytic therapy for carotid and ...

OBJECTIVE Electrocardiography (ECG) may be a practical guiding tool for prognostic infarct sizing in ST elevation acute myocardial infarction (STEAMI). In this study, we sought to find a relation between the infarct size and the change in the QRS axis after thrombolytic therapy. MATERIALS AND METHODS Patients with STEAMI who received thrombolytic therapy were selected retrospectively. The mea...

The medicinal value of earthworm has been widely known since the history of Asian ancient medicine. This present study aims to determine the mechanism of action and effect of a standardized extract of Lumbricus rubellus named as DLBS1033. The fibrinogen degradation, antiplatelet aggregation, and ex vivo antithrombotic assay using human blood were performed to study antithrombotic activity. Fibr...

OBJECTIVE To pool data on the role of thrombolytic agents in cardiopulmonary resuscitation (CPR) and evaluate the efficacy and safety of thrombolysis. MATERIALS AND METHODS The clinical studies in MEDLINE database from 1966 to August 2004 that studied the efficacy and safety in CPR with and without treatment with thrombolytic agents were assessed by a meta-analysis performed to evaluate the e...

The major factor influencing the outcome of thrombolytic therapy for acute myocardial infarction is the " door to needle " time. For every hour that thrombolytic treatment is delayed after the onset of symptoms, 1.6 lives are lost per 1000 patients treated. 1 In many institutions the door to needle time exceeds one hour. Various attempts have been made to reduce unacceptable treatment delays. T...

BACKGROUND Thrombolytic therapy should only be used when expected benefits outweigh the risks. In order to obtain a precise estimation of prognosis, with and without thrombolytic therapy, we postulated that mortality reduction by thrombolytic therapy is a function of the area of myocardium at risk for necrosis. We developed a model to estimate the myocardial area at risk for necrosis from clini...

The purpose of this communication is to review briefly the agents available at the present time for use in thrombolytic therapy and to indicate why we believe that at the present time streptokinase is the only suitable agent for extended clinical trial. An account will then be given of the use of streptokinase administered by local perfusion in the treatment of peripheral arterial occlusion and...

Thrombolytic therapy is a practical, effective approach to the management of acute myocardial infarction that is widely used in Europe today. Early European trials demonstrated a clear reduction in mortality in patients who received thrombolytic therapy compared with those given conventional treatment. The findings of experimental studies suggest that early reperfusion of the infarct-related ar...

BACKGROUND Intravenous thrombolysis is an approved treatment method for patients with acute ischemic stroke (AIS) and is recommended by multiple guidelines. However, it seems that it is less frequently used in the developing countries compared to the developed countries. OBJECTIVES The purpose of this study was to estimate the percentage of patients with AIS, eligible for intravenous thrombol...